Scan For Analyst Views: Clovis Oncology, Inc. (CLVS), Inovio Pharmaceuticals, Inc. (INO)

Mindy Sparks
November 18, 2017

The company has market cap of $3.12 billion. It has a 55.01 P/E ratio. The Firm operates through three divisions: Hughes, EchoStar Technologies and EchoStar Satellite Services (ESS).

Clovis Oncology, a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets. About 515,995 shares traded. Finally, Legal & General Group Plc lifted its holdings in shares of Clovis Oncology by 9.4% during the 1st quarter. It has outperformed by 266.01% the S&P500. It was reported on Nov, 17 by "(NASDAQ:CLVS)" was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. Clough Capital Partners L P now holds 83,735 shares valued at $6,900,000. State Street Corp now owns 1,943,480 shares of the biopharmaceutical company's stock valued at $181,966,000 after purchasing an additional 80,171 shares during the last quarter. The company's stock had a trading volume of 1,158,800 shares, compared to its average volume of 1,860,937. The New York-based Act Ii Management Lp has invested 6.24% in the stock. The fund owned 10,575 shares of the biopharmaceutical company's stock after buying an additional 1,600 shares during the period.

Analysts await Conn's Inc (NASDAQ:CONN) to report earnings on December, 5. They expect $0.34 earnings per share, up 13.33% or $0.04 from last year's $0.3 per share. SATS's profit will be $10.53M for 135.77 P/E if the $0.11 EPS becomes a reality. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.18) by ($0.06). About 20,873 shares traded. Conn's Inc (NASDAQ:CONN) has risen 45.89% since November 17, 2016 and is uptrending. It has outperformed by 31.26% the S&P500.

Among 6 analysts covering CONN'S (NASDAQ:CONN), 4 have Buy rating, 0 Sell and 2 Hold. It turned negative, as 33 investors sold CLVS shares while 56 reduced holdings. Therefore 67% are positive. Ubs Asset Mgmt Americas stated it has 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $93.00 target price on shares of Clovis Oncology in a report on Thursday, August 10th. As per Wednesday, September 16, the company rating was maintained by SP Angel. Cann restated a "hold" rating on shares of Clovis Oncology in a research note on Monday, July 31st. BidaskClub raised shares of Clovis Oncology from a "buy" rating to a "strong-buy" rating in a report on Wednesday, August 2nd. The firm has "Neutral" rating by Piper Jaffray given on Monday, April 4. The firm earned "Buy" rating on Tuesday, December 1 by Stifel Nicolaus. Franklin Resources Inc. grew its position in Clovis Oncology by 70.3% during the 2nd quarter. The firm has "Buy" rating by KeyBanc Capital Markets given on Thursday, September 7. Its down 0.66, from 2.47 in 2017Q1. Alliancebernstein L.P. now owns 958,721 shares of the biopharmaceutical company's stock valued at $89,765,000 after acquiring an additional 204,599 shares in the last quarter. Dimensional Fund Lp has 24,866 shares for 0% of their portfolio. Harbourvest Partners Limited Liability holds 21,437 shares. Farallon Cap Management Limited Co invested 0.59% in Clovis Oncology Inc (NASDAQ:CLVS).

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Wednesday, November 1st. Phocas Financial Corp. acquired a new position in shares of Clovis Oncology in the 2nd quarter worth approximately $112,000. Two Sigma Securities Lc holds 11,100 shares. Shell Asset Mngmt holds 0.02% or 7,680 shares. Jpmorgan Chase accumulated 43,215 shares. Creative Planning invested 0.01% in Clovis Oncology Inc (NASDAQ:CLVS). The short-interest ratio increased to 6.0 and the percentage of shorted shares is 0.14% as of October 13. American Int Group Inc Inc invested in 24,416 shares or 0.01% of the stock. Redmile Group Llc, a California-based fund reported 764,389 shares. Prelude Capital Ltd Liability Co invested in 0.16% or 17,736 shares. During the same quarter last year, the firm posted ($1.70) earnings per share. equities analysts anticipate that Clovis Oncology, Inc. will post -7.63 earnings per share for the current fiscal year. They expect $-1.27 earnings per share, up 30.60% or $0.56 from last year's $-1.83 per share.

Palo Alto Investors Llc holds 14.55% of its portfolio in Clovis Oncology Inc for 3.33 million shares.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article